Lorinda K. Baker

Lorinda K. Baker

Auto-generated profile, based on publicly available information

Lorinda K. Baker

Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA; Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KDKarie N. Dahlgren
Karie N. Dahlgren
AMArlene M. Manelli
Arlene M. Manelli
WSW. Blaine Stine
W. Blaine Stine
LBLorinda K. Baker
Lorinda K. Baker
GKGrant A. Krafft
Grant A. Krafft
MLMary Jo LaDu
Mary Jo LaDu
Genetic evidence predicts a causative role for amyloid-beta (A beta) in Alzheimer's disease. Recent debate has focused on whether fibrils (amyloid) or soluble oligomers of A beta are the active species that contribute to neurodegeneration and dementia. We developed two aggregation protocols for the consistent production of stable oligomeric or fibrillar preparations of A beta-(1-42). Here we report that oligomers inhibit neuronal viability 10-fold more than fibrils and approximately 40-fold more than unaggregated peptide, with oligomeric A beta-(1-42)-induced inhibition significant at 10 nm. Under A beta-(1-42) oligomer- and fibril-forming conditions, A beta-(1-40) remains predominantly as unassembled monomer and had significantly less effect on neuronal viability than preparations of A beta-(1-42). We applied the aggregation protocols developed for wild type A beta-(1-42) to A beta-(1-42) with the Dutch (E22Q) or Arctic (E22G) mutations. Oligomeric preparations of the mutations exhibited extensive protofibril and fibril formation, respectively, but were not consistently different from wild type A beta-(1-42) in terms of inhibition of neuronal viability. However, fibrillar preparations of the mutants appeared larger and induced significantly more inhibition of neuronal viability than wild type A beta-(1-42) fibril preparations. These data demonstrate that protocols developed to produce oligomeric and fibrillar A beta-(1-42) are useful in distinguishing the structural and functional differences between A beta-(1-42) and A beta-(1-40) and genetic mutations of A beta-(1-42).

1 April 2013 in Behavioural Brain Research
Verified
Journal Article
Closed access
HHHsien-Sung Huang
Hsien-Sung Huang
ABAndrew J. Burns
Andrew J. Burns
RNRandal J. Nonneman
Randal J. Nonneman
LBLorinda K. Baker
Lorinda K. Baker
NRNatallia V. Riddick
Natallia V. Riddick
SMSheryl S. Moy
Sheryl S. Moy

30 April 2003 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MMMichela Marinelli
Michela Marinelli
DCDonald C. Cooper
Donald C. Cooper
LBLorinda K. Baker
Lorinda K. Baker
FWFrancis J. White
Francis J. White

1 September 2013 in Neuropharmacology
Verified
Journal Article
Closed access
BTBrian L. Teng
Brian L. Teng
RNRandal J. Nonneman
Randal J. Nonneman
KAKara L. Agster
Kara L. Agster
VNViktoriya D. Nikolova
Viktoriya D. Nikolova
TDTamara T. Davis
Tamara T. Davis
SMSheryl S. Moy
Sheryl S. Moy

1 February 2014 in Behavioural Brain Research
Verified
Journal Article
Closed access
SMSheryl S. Moy
Sheryl S. Moy
NRNatallia V. Riddick
Natallia V. Riddick
VNViktoriya D. Nikolova
Viktoriya D. Nikolova
BTBrian L. Teng
Brian L. Teng
KAKara L. Agster
Kara L. Agster
JBJames W. Bodfish
James W. Bodfish

1 November 2016 in Neurotoxicology and Teratology
Verified
Journal Article
Closed access
MGMarcoita T. Gilbert
Marcoita T. Gilbert
KSKathleen K. Sulik
Kathleen K. Sulik
EFEric W. Fish
Eric W. Fish
LBLorinda K. Baker
Lorinda K. Baker
DDDeborah B. Dehart
Deborah B. Dehart
SPScott E. Parnell
Scott E. Parnell